Literature DB >> 12873988

Gene expression profiling in polycythemia vera using cDNA microarray technology.

Andrea Pellagatti1, David Vetrie, Cordelia F Langford, Susana Gama, Helen Eagleton, James S Wainscoat, Jacqueline Boultwood.   

Abstract

Polycythemia vera (PV) is a myeloproliferative disorder characterized by an increased proliferation of all three myeloid lineages. The molecular pathogenesis of PV is unknown. Using cDNA microarrays comprising 6000 human genes, we studied the gene expression profile of granulocytes obtained from 11 PV patients compared with granulocytes obtained from healthy individuals. We found that 147 genes were up-regulated by >/==" BORDER="0">2.5 fold in the majority of PV patients. Eleven of these 147 genes were up-regulated in all PV patients studied and may represent a molecular signature for this disorder. An increase in the expression of several protease inhibitors with affinity for proteases that promote apoptosis in neutrophils (e.g., cystatin F, secretory leukocyte protease inhibitor), as well as the up-regulation of a number of antiapoptotic and survival factors was found (e.g., adrenomedullin, p38 mitogen-activated protein kinase). We speculate that the deregulation of these factors may inhibit normal apoptosis and promote cell survival in the granulocytes of patients with PV. These PV-specific expression changes are likely to be biologically important in the pathophysiology of this disorder.

Entities:  

Mesh:

Year:  2003        PMID: 12873988

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

Review 1.  Platelet genomics and proteomics in human health and disease.

Authors:  Iain C Macaulay; Philippa Carr; Arief Gusnanto; Willem H Ouwehand; Des Fitzgerald; Nicholas A Watkins
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

Review 2.  Proteomic approaches to dissect platelet function: Half the story.

Authors:  Dmitri V Gnatenko; Peter L Perrotta; Wadie F Bahou
Journal:  Blood       Date:  2006-08-22       Impact factor: 22.113

3.  Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development.

Authors:  Takeshi Ueda; Masato Sasaki; Andrew J Elia; Iok In Christine Chio; Koichi Hamada; Rikiro Fukunaga; Tak W Mak
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-02       Impact factor: 11.205

4.  Loss of pleckstrin-2 reverts lethality and vascular occlusions in JAK2V617F-positive myeloproliferative neoplasms.

Authors:  Baobing Zhao; Yang Mei; Lan Cao; Jingxin Zhang; Ronen Sumagin; Jing Yang; Juehua Gao; Matthew J Schipma; Yanfeng Wang; Chelsea Thorsheim; Liang Zhao; Timothy Stalker; Brady Stein; Qiang Jeremy Wen; John D Crispino; Charles S Abrams; Peng Ji
Journal:  J Clin Invest       Date:  2017-11-20       Impact factor: 14.808

5.  Quantification of clonal hematopoiesis in polycythemia vera.

Authors:  Udo Siebolts; Murat Ates; Rüdiger Spitz; Jürgen Thiele; Claudia Wickenhauser
Journal:  Virchows Arch       Date:  2005-08-19       Impact factor: 4.064

6.  Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F.

Authors:  Windy Berkofsky-Fessler; Monica Buzzai; Marianne K-H Kim; Steven Fruchtman; Vesna Najfeld; Dong-Joon Min; Fabricio F Costa; Jared M Bischof; Marcelo B Soares; Melanie Jane McConnell; Weijia Zhang; Ross Levine; D Gary Gilliland; Raffaele Calogero; Jonathan D Licht
Journal:  Clin Cancer Res       Date:  2010-07-02       Impact factor: 12.531

7.  Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.

Authors:  Raajit Rampal; Fatima Al-Shahrour; Omar Abdel-Wahab; Jay P Patel; Jean-Philippe Brunel; Craig H Mermel; Adam J Bass; Jennifer Pretz; Jihae Ahn; Todd Hricik; Outi Kilpivaara; Martha Wadleigh; Lambert Busque; D Gary Gilliland; Todd R Golub; Benjamin L Ebert; Ross L Levine
Journal:  Blood       Date:  2014-04-16       Impact factor: 22.113

8.  Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling.

Authors:  Edwin Chen; Philip A Beer; Anna L Godfrey; Christina A Ortmann; Juan Li; Ana P Costa-Pereira; Catherine E Ingle; Emmanouil T Dermitzakis; Peter J Campbell; Anthony R Green
Journal:  Cancer Cell       Date:  2010-11-16       Impact factor: 31.743

9.  HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer.

Authors:  Euan A Stronach; Albandri Alfraidi; Nona Rama; Christoph Datler; James B Studd; Roshan Agarwal; Tankut G Guney; Charlie Gourley; Bryan T Hennessy; Gordon B Mills; Antonello Mai; Robert Brown; Roberto Dina; Hani Gabra
Journal:  Cancer Res       Date:  2011-05-13       Impact factor: 12.701

10.  Prediction of NSCLC recurrence from microarray data with GEP.

Authors:  Russul Al-Anni; Jingyu Hou; Rana Dhia'a Abdu-Aljabar; Yong Xiang
Journal:  IET Syst Biol       Date:  2017-06       Impact factor: 1.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.